These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35298699)

  • 1. Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models.
    DeAngelis N; Ferrante C; Powers G; Sendecki J; Mattson B; Pizutti D; Packman K; Wang W; Trouba K; Nanjunda R; Wheeler J; Brittingham R; Wu SJ; Luo J; Lorenzi MV; Verona RI
    Cancer Chemother Pharmacol; 2022 Apr; 89(4):515-527. PubMed ID: 35298699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.
    Felip E; Moreno V; Morgensztern D; Curigliano G; Rutkowski P; Trigo JM; Calvo A; Kowalski D; Cortinovis D; Plummer R; Maio M; Ascierto PA; Vladimirov VI; Cervantes A; Zudaire E; Hazra A; T'jollyn H; Bandyopadhyay N; Greger JG; Attiyeh E; Xie H; Calvo E
    Cancer Chemother Pharmacol; 2022 Apr; 89(4):499-514. PubMed ID: 35298698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biophysical and Immunological Characterization and
    Hutchins B; Starling GC; McCoy MA; Herzyk D; Poulet FM; Dulos J; Liu L; Kang SP; Fayadat-Dilman L; Hsieh M; Andrews CL; Ayanoglu G; Cullen C; Malefyt RW; Kastelein RA; Saux SL; Lee J; Li S; Malashock D; Sadekova S; Soder G; van Eenennaam H; Willingham A; Yu Y; Streuli M; Carven GJ; van Elsas A
    Mol Cancer Ther; 2020 Jun; 19(6):1298-1307. PubMed ID: 32229606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform.
    Gjetting T; Gad M; Fröhlich C; Lindsted T; Melander MC; Bhatia VK; Grandal MM; Dietrich N; Uhlenbrock F; Galler GR; Strandh M; Lantto J; Bouquin T; Horak ID; Kragh M; Pedersen MW; Koefoed K
    MAbs; 2019; 11(4):666-680. PubMed ID: 31046547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties.
    Zhang J; Huang Y; Xi G; Zhang F
    MAbs; 2020; 12(1):1724751. PubMed ID: 32106752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human
    Burova E; Hermann A; Waite J; Potocky T; Lai V; Hong S; Liu M; Allbritton O; Woodruff A; Wu Q; D'Orvilliers A; Garnova E; Rafique A; Poueymirou W; Martin J; Huang T; Skokos D; Kantrowitz J; Popke J; Mohrs M; MacDonald D; Ioffe E; Olson W; Lowy I; Murphy A; Thurston G
    Mol Cancer Ther; 2017 May; 16(5):861-870. PubMed ID: 28265006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy.
    Li F; Li J; Yin K; Zhang J; Li ZH; Lu L; Bao YW; Qin Z; Zheng Y; Yang BT; Li J; Wang X
    Acta Pharmacol Sin; 2021 Jan; 42(1):142-148. PubMed ID: 32467569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models.
    Kumar S; Ghosh S; Sharma G; Wang Z; Kehry MR; Marino MH; Neben TY; Lu S; Luo S; Roberts S; Ramaswamy S; Danaee H; Jenkins D
    MAbs; 2021; 13(1):1954136. PubMed ID: 34313545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.
    Cheng LS; Zhu M; Gao Y; Liu WT; Yin W; Zhou P; Zhu Z; Niu L; Zeng X; Zhang D; Fang Q; Wang F; Zhao Q; Zhang Y; Shen G
    Cell Mol Biol Lett; 2023 May; 28(1):47. PubMed ID: 37259060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
    Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
    Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity.
    Luan Y; Chai D; Peng J; Ma S; Wang M; Ma H; Li X; Fu S; Pan X; Wang X; Qin S; Xu T
    Int Immunopharmacol; 2016 Feb; 31():248-56. PubMed ID: 26773772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human
    Burova E; Hermann A; Dai J; Ullman E; Halasz G; Potocky T; Hong S; Liu M; Allbritton O; Woodruff A; Pei J; Rafique A; Poueymirou W; Martin J; MacDonald D; Olson WC; Murphy A; Ioffe E; Thurston G; Mohrs M
    Mol Cancer Ther; 2019 Nov; 18(11):2051-2062. PubMed ID: 31395688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.
    Wang C; Thudium KB; Han M; Wang XT; Huang H; Feingersh D; Garcia C; Wu Y; Kuhne M; Srinivasan M; Singh S; Wong S; Garner N; Leblanc H; Bunch RT; Blanset D; Selby MJ; Korman AJ
    Cancer Immunol Res; 2014 Sep; 2(9):846-56. PubMed ID: 24872026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments.
    Moreno-Vicente J; Willoughby JE; Taylor MC; Booth SG; English VL; Williams EL; Penfold CA; Mockridge CI; Inzhelevskaya T; Kim J; Chan HTC; Cragg MS; Gray JC; Beers SA
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses.
    Zettl M; Wurm M; Schaaf O; Mostböck S; Tirapu I; Apfler I; Lorenz IC; Frego L; Kenny C; Thibodeau M; Oquendo Cifuentes E; Reschke M; Moll J; Kraut N; Vogt A; Sedgwick JD; Waizenegger IC
    Oncoimmunology; 2022; 11(1):2080328. PubMed ID: 35756842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.
    Fu J; Wang F; Dong LH; Zhang J; Deng CL; Wang XL; Xie XY; Zhang J; Deng RX; Zhang LB; Wu H; Feng H; Chen B; Song HF
    Acta Pharmacol Sin; 2017 May; 38(5):710-718. PubMed ID: 28317872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors.
    Iadonato S; Ovechkina Y; Lustig K; Cross J; Eyde N; Frazier E; Kabi N; Katz C; Lance R; Peckham D; Sridhar S; Talbaux C; Tihista I; Xu M; Guillaudeux T
    Front Immunol; 2023; 14():1311658. PubMed ID: 38152397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.